 Todd Bull
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 45 | 2024 | 1980 | 3.700 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 123 | 1.600 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 243 | 1.190 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 248 | 1.170 |
Why?
| | Vena Cava Filters | 2 | 2020 | 64 | 0.760 |
Why?
| | Epoprostenol | 5 | 2024 | 131 | 0.720 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 162 | 0.710 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 76 | 0.640 |
Why?
| | Airway Obstruction | 1 | 2021 | 162 | 0.620 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 919 | 0.610 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 509 | 0.600 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 197 | 0.570 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 291 | 0.570 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 758 | 0.540 |
Why?
| | Thrombosis | 4 | 2023 | 393 | 0.530 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 41 | 0.500 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 382 | 0.500 |
Why?
| | Vascular Resistance | 5 | 2021 | 366 | 0.490 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 150 | 0.480 |
Why?
| | Exercise Test | 4 | 2024 | 634 | 0.480 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 132 | 0.460 |
Why?
| | Hypoxia | 6 | 2024 | 1199 | 0.460 |
Why?
| | Altitude Sickness | 1 | 2017 | 141 | 0.450 |
Why?
| | Endovascular Procedures | 1 | 2020 | 384 | 0.450 |
Why?
| | Pulmonary Artery | 10 | 2023 | 1134 | 0.430 |
Why?
| | Vasodilator Agents | 4 | 2023 | 331 | 0.420 |
Why?
| | Echocardiography | 2 | 2020 | 647 | 0.410 |
Why?
| | Ventricular Function, Right | 5 | 2024 | 297 | 0.390 |
Why?
| | Humans | 70 | 2026 | 144261 | 0.390 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 918 | 0.380 |
Why?
| | Altitude | 1 | 2017 | 473 | 0.370 |
Why?
| | Anticoagulants | 5 | 2023 | 721 | 0.350 |
Why?
| | Perioperative Care | 1 | 2014 | 230 | 0.350 |
Why?
| | Sulfones | 1 | 2012 | 127 | 0.350 |
Why?
| | Endothelial Cells | 5 | 2011 | 869 | 0.340 |
Why?
| | Oxygen Consumption | 2 | 2024 | 724 | 0.330 |
Why?
| | Blood Cells | 1 | 2010 | 37 | 0.330 |
Why?
| | Walk Test | 3 | 2026 | 80 | 0.310 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 68 | 0.310 |
Why?
| | Hypertension, Portal | 2 | 2020 | 66 | 0.310 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 324 | 0.300 |
Why?
| | Piperazines | 1 | 2012 | 380 | 0.300 |
Why?
| | Blood Coagulation | 3 | 2021 | 268 | 0.300 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 286 | 0.300 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 94 | 0.290 |
Why?
| | Virus Diseases | 1 | 2011 | 216 | 0.280 |
Why?
| | Exercise | 5 | 2026 | 2193 | 0.280 |
Why?
| | Lung | 8 | 2022 | 4108 | 0.250 |
Why?
| | Acute Lung Injury | 1 | 2010 | 302 | 0.250 |
Why?
| | Blood Vessels | 1 | 2008 | 171 | 0.250 |
Why?
| | Time Factors | 2 | 2017 | 7155 | 0.240 |
Why?
| | Middle Aged | 21 | 2026 | 35762 | 0.240 |
Why?
| | Heart Ventricles | 5 | 2024 | 756 | 0.240 |
Why?
| | Male | 29 | 2026 | 72035 | 0.230 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 9 | 0.230 |
Why?
| | Microarray Analysis | 1 | 2005 | 117 | 0.230 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 546 | 0.230 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 452 | 0.220 |
Why?
| | Accelerometry | 1 | 2026 | 119 | 0.220 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 557 | 0.210 |
Why?
| | Female | 28 | 2026 | 77976 | 0.210 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 275 | 0.210 |
Why?
| | Aromatase Inhibitors | 1 | 2024 | 75 | 0.210 |
Why?
| | Castleman Disease | 1 | 2003 | 16 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1782 | 0.180 |
Why?
| | Heparin | 2 | 2021 | 243 | 0.180 |
Why?
| | Biopsy | 1 | 2005 | 1075 | 0.180 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 18 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 600 | 0.180 |
Why?
| | Endothelium, Vascular | 6 | 2007 | 963 | 0.170 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 24 | 0.170 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.160 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.160 |
Why?
| | Aromatase | 1 | 2020 | 32 | 0.160 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 448 | 0.160 |
Why?
| | Aged | 13 | 2026 | 25850 | 0.160 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 23 | 0.160 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 430 | 0.160 |
Why?
| | Thrombectomy | 1 | 2020 | 77 | 0.150 |
Why?
| | Drug Resistance | 1 | 2020 | 153 | 0.150 |
Why?
| | Tuberculosis | 1 | 2003 | 289 | 0.150 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 142 | 0.150 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 244 | 0.150 |
Why?
| | Vascular Stiffness | 1 | 2023 | 462 | 0.140 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 60 | 0.140 |
Why?
| | Risk Factors | 7 | 2018 | 10699 | 0.140 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1054 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.130 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 67 | 0.130 |
Why?
| | Estrogens | 1 | 2020 | 380 | 0.130 |
Why?
| | Acute Disease | 1 | 2020 | 1028 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.130 |
Why?
| | Critical Illness | 2 | 2021 | 889 | 0.130 |
Why?
| | Purines | 2 | 2023 | 187 | 0.130 |
Why?
| | Hemodynamics | 2 | 2014 | 1119 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 479 | 0.120 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 109 | 0.120 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 38 | 0.120 |
Why?
| | Risk Assessment | 3 | 2023 | 3637 | 0.120 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 320 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1682 | 0.120 |
Why?
| | Adult | 15 | 2024 | 40262 | 0.110 |
Why?
| | Systole | 1 | 2016 | 178 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 382 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 377 | 0.110 |
Why?
| | Treatment Outcome | 8 | 2024 | 11643 | 0.110 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1050 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 510 | 0.110 |
Why?
| | Cohort Studies | 3 | 2017 | 5935 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2016 | 298 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 686 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2023 | 17009 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 93 | 0.110 |
Why?
| | Prognosis | 3 | 2013 | 4278 | 0.110 |
Why?
| | Blood Pressure | 2 | 2016 | 1759 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2020 | 916 | 0.100 |
Why?
| | ROC Curve | 1 | 2016 | 612 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 567 | 0.100 |
Why?
| | Heart Failure | 2 | 2020 | 2314 | 0.100 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 112 | 0.100 |
Why?
| | Anesthetics | 1 | 2014 | 99 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 659 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 456 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 23 | 0.090 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 573 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 154 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1559 | 0.090 |
Why?
| | Drug Storage | 1 | 2012 | 53 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5389 | 0.090 |
Why?
| | Drug Stability | 1 | 2012 | 164 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 25 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 3157 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 89 | 0.090 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 12 | 0.090 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 36 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 48 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 83 | 0.090 |
Why?
| | Europe | 1 | 2012 | 412 | 0.090 |
Why?
| | Hyponatremia | 1 | 2011 | 43 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3403 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 115 | 0.080 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2020 | 3592 | 0.080 |
Why?
| | Antithrombins | 1 | 2011 | 70 | 0.080 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 28 | 0.080 |
Why?
| | Ultrasonography | 2 | 2011 | 768 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2024 | 2025 | 0.080 |
Why?
| | Quality of Life | 4 | 2026 | 3166 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3857 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 340 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2111 | 0.080 |
Why?
| | Demography | 1 | 2010 | 284 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.070 |
Why?
| | Registries | 3 | 2022 | 2382 | 0.070 |
Why?
| | Cluster Analysis | 1 | 2010 | 519 | 0.070 |
Why?
| | Vasopressins | 1 | 2009 | 60 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 379 | 0.070 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 981 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 121 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 144 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2637 | 0.070 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 111 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2005 | 66 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 660 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 7970 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 370 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 238 | 0.060 |
Why?
| | Research Design | 1 | 2013 | 1129 | 0.060 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2005 | 162 | 0.060 |
Why?
| | Acrolein | 1 | 2007 | 22 | 0.060 |
Why?
| | Animals | 10 | 2017 | 38030 | 0.060 |
Why?
| | United States | 4 | 2022 | 15876 | 0.060 |
Why?
| | Survival Analysis | 1 | 2010 | 1382 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1533 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1172 | 0.060 |
Why?
| | Colorado | 1 | 2017 | 4562 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 150 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 850 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 26 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 73 | 0.060 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1646 | 0.060 |
Why?
| | Lymphokines | 2 | 2002 | 130 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4146 | 0.050 |
Why?
| | Apoptosis | 3 | 2008 | 2430 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 736 | 0.050 |
Why?
| | Cattle | 2 | 2017 | 999 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 780 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1128 | 0.050 |
Why?
| | Vasodilation | 3 | 2010 | 522 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2003 | 32 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 44 | 0.050 |
Why?
| | E-Selectin | 1 | 2003 | 61 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 388 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1834 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 205 | 0.050 |
Why?
| | Veins | 1 | 2003 | 68 | 0.050 |
Why?
| | Blood | 1 | 2003 | 109 | 0.050 |
Why?
| | Biomarkers | 4 | 2013 | 4254 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 688 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 22281 | 0.050 |
Why?
| | Hydralazine | 1 | 2022 | 6 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 574 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 383 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 143 | 0.050 |
Why?
| | Hydrazones | 1 | 2022 | 26 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1044 | 0.050 |
Why?
| | Postmenopause | 1 | 2024 | 391 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 322 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 56 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 250 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 185 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 50 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4556 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 220 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1255 | 0.040 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Vascular Remodeling | 1 | 2023 | 204 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 267 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.040 |
Why?
| | Brachial Artery | 2 | 1999 | 206 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 502 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 106 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 70 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 230 | 0.040 |
Why?
| | Proteomics | 2 | 2022 | 1191 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5813 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 336 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1468 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 439 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1715 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 161 | 0.040 |
Why?
| | Mass Screening | 1 | 2007 | 1332 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2603 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1322 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2022 | 299 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2926 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 809 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2917 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2017 | 40 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 371 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 2088 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 103 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 698 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 52 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 221 | 0.030 |
Why?
| | Education | 1 | 2017 | 104 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2020 | 389 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 171 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 878 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2494 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5221 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 538 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 494 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2016 | 901 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2020 | 822 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2143 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 842 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2424 | 0.020 |
Why?
| | Perioperative Period | 1 | 2012 | 71 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2730 | 0.020 |
Why?
| | Mice | 2 | 2007 | 18329 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 25 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 50 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 197 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 147 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 80 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 112 | 0.020 |
Why?
| | Nitric Oxide | 2 | 2010 | 897 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 245 | 0.020 |
Why?
| | Introns | 1 | 2011 | 254 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8243 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 171 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 236 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2877 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 192 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 284 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 266 | 0.020 |
Why?
| | Leg | 1 | 2011 | 239 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 338 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2002 | 557 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2829 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 39 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 612 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 257 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 486 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1327 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 68 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 165 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 184 | 0.020 |
Why?
| | Mutation | 3 | 2005 | 4085 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 5988 | 0.010 |
Why?
| | Research | 1 | 2009 | 428 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2270 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1487 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 13990 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 320 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1497 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 375 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 90 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1739 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 84 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1867 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2840 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 109 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2182 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 420 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 358 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3842 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 355 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2001 | 157 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 824 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2001 | 217 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2916 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 402 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6021 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 586 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 7 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 12 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 14 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7180 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 67 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 194 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 84 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 176 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 211 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 413 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 797 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 254 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 998 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 709 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|